Quinupristin/dalfopristin

Quinupristin/dalfopristin

Quinupristin (top) and dalfopristin (bottom)
Combination of
Quinupristin	Streptogramin antibiotic
Dalfopristin	Streptogramin antibiotic
Clinical data
Pregnancy category	AU:B3 B (U.S.)
Routes of administration	IV
ATC code	J01FG02 ( WHO )
Legal status
Legal status	US: ℞-only
Identifiers
CAS Number	126602-89-9  N
PubChem CID	23724510
ChemSpider	21106373  Y
NY  (what is this?)    (verify)

Quinupristin/dalfopristin, or quinupristin-dalfopristin, (pronunciation: kwi NYOO pris tin / dal FOE pris tin) (trade name Synercid) is a combination of two antibiotics used to treat infections caused by staphylococci and by vancomycin-resistant Enterococcus faecium .

Quinupristin and dalfopristin are both streptogramin antibiotics, derived from pristinamycin. Quinupristin is derived from pristinamycin IA; dalfopristin from pristinamycin IIA. They are combined in a weight-to-weight ratio of 30% quinupristin to 70% dalfopristin. Discontinued 2022, there are no other manufacturers of this medication.

Administration

Intravenous, usually 7.5 mg/kg every 8 hours (infections/life threatening VRSA); every 12 hours (skin infections). No renal dosing adjustments, hepatic dosing adjustments are not defined, consider reducing dose.

Mechanism of action

Quinupristin and dalfopristin are protein synthesis inhibitors in a synergistic manner. While each of the two is only a bacteriostatic agent, the combination shows bactericidal activity.

• Dalfopristin binds to the 23S portion of the 50S ribosomal subunit, and changes the conformation of it, enhancing the binding of quinupristin ^[1] by a factor of about 100. In addition, it inhibits peptidyl transfer. ^[1]
• Quinupristin binds to a nearby site on the 50S ribosomal subunit and prevents elongation of the polypeptide, ^[1] as well as causing incomplete chains to be released. ^[1]

Pharmacokinetics

Clearance by the liver CYP450:3A4 inhibitor, half-life quinupristin 0.8 hours, dalfopristin 0.7 hours (with persistence of effects for 9–10 hours).

Side effects

 [2] 

Serious:

1. C.diff-associated diarrhea
2. superinfection
3. anaphylactoid reactions
4. angioedema

Common:

1. Joint aches (arthralgia) or muscle aches (myalgia)
2. Nausea, diarrhea (C. diff associated) or vomiting
3. Rash or itching
4. Headache
5. Hyperbilirubinemia
6. Anemia
7. Thrombophlebitis

Drug interactions

The drug inhibits P450 and enhances the effects of terfenadine, astemizole, indinavir, midazolam, calcium channel blockers, warfarin, cisapride and ciclosporin.

References

1. Denyer SP, Hodges N, Gorman SP, eds. (2004). Hugo and Russell's Pharmaceutical microbiology (7th ed.). Blackwell Science. p. 212. ISBN   978-0-632-06467-0.
2. Epocrates v 19.5

Further reading

• Allington DR, Rivey MP (January 2001). "Quinupristin/dalfopristin: a therapeutic review". Clinical Therapeutics. 23 (1): 24–44. doi:10.1016/S0149-2918(01)80028-X. PMID   11219478.
• Lamb HM, Figgitt DP, Faulds D (December 1999). "Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections". Drugs. 58 (6): 1061–97. doi:10.2165/00003495-199958060-00008. PMID   10651391. S2CID   209144323.
• Manzella JP (December 2001). "Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections". American Family Physician. 64 (11): 1863–6. PMID   11764864..
• Paradisi F, Corti G, Messeri D (January 2001). "Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics" (PDF). The Medical Clinics of North America. 85 (1): 1–17. doi:10.1016/s0025-7125(05)70302-3. hdl: 2158/329747 . PMID   11190346.
• "Synercid". U.S. Food and Drug Administration. Archived from the original on 2007-06-18.